Antibodies play an essential role in host defence against pathogens by recognizing
microorganisms or infected cells. Although preventing pathogen entry is one potential …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

RTS, S is an advanced malaria vaccine candidate and confers significant protection against
Plasmodium falciparum infection in humans. Little is known about the molecular …

Vaccine development has the potential to be accelerated by coupling tools such as systems
immunology analyses and controlled human infection models to define the protective …

Over 75% of malaria-attributable deaths occur in children under the age of 5 years.
However, the first malaria vaccine recommended by the World Health Organization (WHO) …

Control of intracellular parasites responsible for malaria requires host IFN-γ+ T-bet+ CD4+ T
cells (Th1 cells) with IL-10 produced by Th1 cells to mitigate the pathology induced by this …

Background. Three full doses of RTS, S/AS01 malaria vaccine provides partial protection
against controlled human malaria parasite infection (CHMI) and natural exposure …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

IL-10 produced by CD4+ T cells suppresses inflammation by inhibiting T cell functions and
the upstream activities of antigen presenting cells (APCs). IL-10 was first identified in Th2 …

Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …